Peptide compounding sits at the center of US peptide-access policy in 2026. The April 23, 2026 removal of twelve peptides from FDA Category 2 — including BPC-157, GHK-Cu (injectable), TB-500, KPV, MOTS-C, Semax, Selank, AOD-9604, CJC-1295, ipamorelin, and Epitalon — opened a 90-day window before the July 23-24 PCAC meeting where seven of them go to a vote for 503A bulks list eligibility (BPC-157, KPV, TB-500, MOTS-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2). The public docket (FDA-2025-N-6895) closes July 22.
On the GLP-1 side, the FDA's April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closed for comment June 29. Telehealth platforms (Hims & Hers, LifeMD) migrated to branded supply via Novo and Lilly partnerships through Q1-Q2 2026; Hims & Hers acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities, positioning for the PCAC outcome. Analyst Jonah Lupton projects Hims could generate $10-19B in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets.
Enforcement layered alongside reclassification. The FDA issued 50+ warning letters to peptide vendors and compounders in 2024-2025; the Alabama Board of Medical Examiners (May 26, 2026) and Ohio State Board of Pharmacy (February 2026) added state-level prescribing restrictions. The EVEXIAS/FarmaKeio April 2024 APA lawsuit against the FDA set the legal counterpush in motion. Stories here cover the compounding-pharmacy regulatory thread end to end. See [[pcac]], [[503a]], [[503b]], and [[gray-market]] for adjacent threads.
The FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 at the agency's White Oak campus (Silver Spring, Maryland) reaches its first procedural cutoff next Tuesday: June 30, 2026 is the deadline to register for oral testimony in the public-comment portion of the meeting. Written comments to docket FDA-2025-N-6895 at regulations.gov must arrive by 11:59 PM ET July 22, 2026 (one day before the meeting opens). The Committee will discuss BPC-157, KPV, TB-500, and MOTS-C on Day 1 (July 23) and Emideltide/DSIP, Semax, and Epitalon on Day 2 (July 24). All seven peptides came off FDA Category 2 effective April 23, 2026. PCAC recommendations are advisory: the agency makes the final 503A bulks list decision, and the Hims & Hers (HIMS) stock breakout above $30 reflected market consensus that the July vote will tilt toward eligibility. Lengea Law and PeptideClarity have both published prescriber-facing trackers ahead of the meeting.
Hims & Hers Health (NYSE: HIMS) broke above $30 on June 22, 2026 for the first time since April, finishing the month +36% — its best month since March — on rising investor confidence in the company's peptide platform ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Leerink called the PCAC meeting a key catalyst, framing peptides as Hims' next major product category supporting growth beyond 2027. FirstWave Fund CEO Jonah Lupton projected Hims could generate $10-19 billion in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' signaling deeper wearable connectivity. The June 22-23 stock move reflects the broader market consensus that PCAC will reclassify the seven peptides under review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) and open compounding-pharmacy supply channels.
The Ohio State Board of Pharmacy released a February 18, 2026 update to its peptide compounding guidance establishing state-specific requirements that layer on top of federal 503A rules. The Ohio guidance requires all compounded peptides to be prepared pursuant to a valid patient-specific prescription from an Ohio-licensed practitioner, with detailed prescription documentation and provider-verification protocols; pharmacies cannot compound peptides on the FDA list of substances withdrawn for safety or effectiveness reasons. The guidance followed late-2025 and early-2026 enforcement actions in which at least three Ohio pharmacies received consent agreements and fines for peptide compounding violations. Together with the Alabama Board of Medical Examiners' May 26 notice prohibiting non-FDA-approved peptide prescribing, Ohio's update establishes a clear state-level enforcement pattern ahead of the July 23-24 PCAC meeting.
Pharmacy Times hosted a CME-eligible virtual symposium May 19 (1:00-2:30 PM EDT) framing the post-RFK Jr. peptide moment for hospital and retail pharmacists. The agenda crossed the wellness-clinic side (BPC-157, TB-500, CJC-1295, GHK-Cu after the April 22 503A Category-2 removal) with the FDA-approved peptide side (semaglutide, tirzepatide, liraglutide, navepegritide, paltusotine) and walked attendees through the July 23-24 PCAC vote calculus and patient counseling around compounded GLP-1 risk.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.